Large database study probes lung risk of common breast cancer drug

NCT ID NCT07096024

Completed Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study looks at the risk of interstitial lung disease (ILD) in people with inoperable or recurrent breast cancer who take the drug palbociclib (Ibrance) combined with fulvestrant. Researchers will compare this group to patients taking fulvestrant alone, using data from over 400 hospitals in Japan. The goal is to understand whether palbociclib increases the chance of ILD and what factors might make someone more vulnerable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: palbociclib (Ibrance) plus fulvestrant
What this could lead to: If successful, this could help doctors understand the risk of lung inflammation (interstitial lung disease) in breast cancer patients treated with palbociclib, leading to safer use.
What could go wrong: This is an observational study using existing medical records, not a controlled trial. It can show associations but cannot prove cause and effect. Results may be influenced by unmeasured factors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST NEOPLASMS

Contacts and locations

Show contact details

Locations

Pfizer

New York, New York, 10001, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.